These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10737375)

  • 21. [Aromatase inhibitors of the 3rd generation. What can the "pill against breast cancer" really do?].
    Junker A; Wiedemann GJ; Possinger K
    MMW Fortschr Med; 2002 Jan; 144(5):46-8. PubMed ID: 11883037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New generation aromatase inhibitors--from the advanced to the adjuvant setting.
    Buzdar AU
    Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S13-7; discussion S33-5. PubMed ID: 12353818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local endocrine effects of aromatase inhibitors within the breast.
    Miller WR; Dixon JM
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):93-102. PubMed ID: 11850212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aromatase inhibitors in breast cancer therapy.
    Buzdar AU
    Clin Breast Cancer; 2003 Nov; 4 Suppl 2():S84-8. PubMed ID: 14667279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
    Michaud LB; Buzdar AU
    Drug Saf; 1999 Oct; 21(4):297-309. PubMed ID: 10514021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
    Lønning PE
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):12-5. PubMed ID: 9741783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
    Dixon JM; Love CD; Renshaw L; Bellamy C; Cameron DA; Miller WR; Leonard RC
    Endocr Relat Cancer; 1999 Jun; 6(2):227-30. PubMed ID: 10731113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aromatase inhibitors and their application in breast cancer treatment*.
    Brodie AM; Njar VC
    Steroids; 2000 Apr; 65(4):171-9. PubMed ID: 10713305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
    Nabholtz JM; Reese DM
    Breast Cancer; 2001; 8(4):305-9. PubMed ID: 11791122
    [No Abstract]   [Full Text] [Related]  

  • 31. New aromatase inhibitors in the treatment of advanced breast cancer.
    Crucitta E; Lorusso V; Attolico M; Sambiasi D; Mazzei A; De Lena M
    Int J Oncol; 2000 Nov; 17(5):1037-41. PubMed ID: 11029510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C
    Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
    Kleeberg UR; Dowsett M; Carrion RP; Dodwell DJ; Vorobiof DA; Aparicio LA; Robertson JF
    Oncology; 1997; 54 Suppl 2():19-22. PubMed ID: 9394856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evolving role of aromatase inhibitors in breast cancer.
    Mokbel K
    Int J Clin Oncol; 2002 Oct; 7(5):279-83. PubMed ID: 12402060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
    Roseman BJ; Buzdar AU; Singletary SE
    J Surg Oncol; 1997 Nov; 66(3):215-20. PubMed ID: 9369969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.
    Harper-Wynne C; Coombes RC
    Eur J Cancer; 1999 May; 35(5):744-6. PubMed ID: 10505035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
    Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
    Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critics question price of success in halted clinical trial of aromatase inhibitor letrozole.
    Twombly R
    J Natl Cancer Inst; 2003 Dec; 95(23):1738-9. PubMed ID: 14652229
    [No Abstract]   [Full Text] [Related]  

  • 39. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
    Eisen A; Trudeau M; Shelley W; Messersmith H; Pritchard KI
    Cancer Treat Rev; 2008 Apr; 34(2):157-74. PubMed ID: 18164821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aromatase inhibitors in breast cancer.
    Brodie A
    Trends Endocrinol Metab; 2002 Mar; 13(2):61-5. PubMed ID: 11854020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.